**Thursday, October 24, 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-08:40</td>
<td>Welcome</td>
<td>Bob Löwenberg (Rotterdam), Hartmut Döhner (Ulm), Martin Tallman (New York)</td>
<td>Estoril, Portugal</td>
</tr>
<tr>
<td>08:40-08:55</td>
<td>SESSION I - LEUKEMIA STEM CELLS</td>
<td>Stem cells in human AML</td>
<td>Ravindra Majeti (Stanford)</td>
</tr>
<tr>
<td>08:55-09:00</td>
<td></td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>09:00-09:15</td>
<td>Molecular control and therapy</td>
<td>Andreas Trumpp (Heidelberg)</td>
<td></td>
</tr>
<tr>
<td>09:15-09:20</td>
<td>resistance of AML stem cells</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>09:20-09:35</td>
<td>Therapeutic targeting AML</td>
<td>TBA</td>
<td></td>
</tr>
<tr>
<td>09:35-09:40</td>
<td>stem cells</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>09:40-10:10</td>
<td>Panel discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:10-10:40</td>
<td>Coffee Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:40-10:55</td>
<td>SESSION II - CLONAL</td>
<td>The biological and clinical impact</td>
<td>Siddharta Jaiswal (Stanford)*</td>
</tr>
<tr>
<td>10:55-11:00</td>
<td>HEMATOPOIESIS AND CLONAL</td>
<td>of clonal hematopoiesis</td>
<td></td>
</tr>
<tr>
<td>11:00-11:15</td>
<td>DIVERSITY</td>
<td>Clonal hematopoiesis: predicting development</td>
<td>Liran Shlush (Rehovot)</td>
</tr>
<tr>
<td>11:15-11:20</td>
<td></td>
<td>of AML</td>
<td></td>
</tr>
<tr>
<td>11:20-11:35</td>
<td></td>
<td>DNMT3A and mechanisms of regulating clonal</td>
<td>Peggy Goodell (Houston)</td>
</tr>
<tr>
<td>11:35-11:40</td>
<td></td>
<td>diversity in bone marrow</td>
<td></td>
</tr>
</tbody>
</table>
11:40-12:10  Panel discussion

12:10-13:50  Lunch

12:40-13:40  3 Simultaneous Meet the Expert Sessions

1. Treatment of molecular subsets of AML  Eytan Stein (New York)
2. Introducing novel drugs in our current treatment algorithm of AML  Andrew Wei (Melbourne)
3. Taking advantage of MRD assessment in clinical practice  Gert Ossenkoppele (Amsterdam)

12:40-13:40  Time slot for a satellite symposium

SESSION III - GENETICS AND EPIGENETICS
Chairs: TBA

13:50-14:05  The AML genome(s) and epigenome(s)  Tim Ley (Saint-Louis)
14:05-14:10  Discussion

14:10-14:25  Enhancer and 3D genome remodelling in the induction and maintenance of leukemia  Brian Huntly (Cambridge)
14:25-14:30  Discussion

14:30-14:45  Molecular breakdown of EVI1-AML  Ruud Delwel (Rotterdam)
14:45-14:50  Discussion

14:50-15:05  Mutational Cooperativity and AML Pathogenesis  Ross Levine (New York)
15:05-15:10  Discussion

15:10-15:25  Role of MBD4 in AML development  Ian Majewski (Melbourne)
15:25-15:30  Discussion

15:30-16:00  Panel discussion

16:00-16:30  Coffee break

SESSION IV - PRELEUKEMIC CONDITIONS
Chairs: TBA

16:30-16:45  Molecular mechanisms driving malignant transformation of severe congenital neutropenia  Ivo Touw (Rotterdam)
16:45-16:50  Discussion

16:50-17:05  Inherited bone marrow failure as a preleukemic condition  Jean Soulier (Paris)
17:05-17:10  Discussion

17:10-17:25  Marrow Failure and AML Development  Akiko Shimamura (Boston)
17:25-17:30  Discussion

17:30-17:45  Mechanisms of progression of the MPNs to AML  John Crispino (Chicago)
17:45-17:50  Discussion
17:50-18:05  Recognition of patients with germline susceptibility to myeloid malignancies  
Lucy Godley (Chicago)

18:05-18:10  Discussion

18:10-18:40  Panel discussion

18:40-20:15  On-Site Get-Together and Poster Walk (Cocktails and stand up buffet dinner for all)

---

Friday, October 25, 2019

08:00-09:00  Time slot for a satellite symposium

**SESSION V: MOLECULAR THERAPEUTICS I**  
Chairs: TBA

09:15-09:30  CRISPR and drug screens for therapeutics of AML  
Kimberley Stegmaier (Boston)

09:30-09:35  Discussion  

09:35-09:50  Targeting Chromatin Complexes in AML  
Scott Armstrong (Boston)

09:50-09:55  Discussion  

09:55-10:10  Bcl-2/Mcl-1 targeting (translational aspects)  
Andrew Roberts (Melbourne)

10:10-10:15  Discussion  

10:15-10:30  Targeting RUNX1  
Guy Sauvageau (Montreal)

10:30-10:35  Discussion  

10:35-11:05  Panel discussion

11:05-11:35  Coffee break

**SESSION VI: BIOLOGY OF MINIMAL RESIDUAL DISEASE**  
Chairs: TBA

11:35-11:50  Molecular MRD  
Peter Valk (Rotterdam)

11:50-11:55  Discussion  

11:55-12:10  Single Cell MRD in AML  
Paresh Vyas (Oxford)

12:10-12:15  Discussion  

12:15-12:30  Flow Cytometric MRD  
Jacqueline Cloos (Amsterdam)

12:30-12:35  Discussion  

12:35-13:05  Panel discussion

13:05-14:45  Lunch
13:35-14:35  3 Simultaneous Meet the Expert Sessions

1. Integrating molecular diagnostics in clinical management  Peter Valk (Rotterdam)
2. Treatment of the older patient with AML  Hartmut Döhner (Ulm)
3. Trial design  Bob Löweberg (Rotterdam)

13:35-14:35  Time slot for a satellite symposium

SESSION VII: IMMUNOTHERAPEUTIC TARGETING
Chairs: TBA

14:45-15:00  CAR T cells targeting CD44v6  Monica Casucci (Milan)
15:00-15:05  Discussion
15:05-15:20  Anti 123 bispecific mAb  John DiPersio (Saint-Louis)
15:20-15:25  Discussion
15:25-15:40  TBA
15:40-15:45  Discussion
15:45-16:00  Immune targeting of tumor necrosis factor receptors/CD70 in leukemia  Adrian Ochsenbein (Bern)
16:00-16:05  Discussion
16:05-16:35  Panel discussion

16:35-17:05  Coffee Break

SESSION VIII: MOLECULAR THERAPEUTICS II
Chairs: TBA

17:05-17:20  FLT3 inhibition  Alexander Perl (Philadelphia)
17:20-17:25  Discussion
17:25-17:40  Effects of FLT3-ITD on Myeloid Differentiation  Martin Carroll (Philadelphia)
17:40-17:45  Discussion
17:45-18:00  Inhibition of FLT3-ITD to enhance GVL effects  Robert Zeiser (Freiburg)
18:00-18:05  Discussion
18:05-18:20  FLT3 inhibitor therapeutic combinations  Cathy Smith (San Francisco)
18:20-18:25  Discussion
18:25-18:55  Panel discussion

19:15-20:15  Time slot for a satellite symposium
Saturday, October 26, 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-09:00</td>
<td>Time slot for a satellite symposium</td>
</tr>
<tr>
<td>09:15-09:30</td>
<td>MDM2 P53 targeting</td>
</tr>
<tr>
<td>09:35-09:50</td>
<td>Clinical developments of Bcl-2/Mcl-1 targeting</td>
</tr>
<tr>
<td>09:55-10:10</td>
<td>Targeting dihydroorotate dehydrogenase</td>
</tr>
<tr>
<td>10:15-10:30</td>
<td>Targeting IDH1/IDH2</td>
</tr>
<tr>
<td>10:35-11:05</td>
<td>Panel discussion</td>
</tr>
<tr>
<td>11:05-11:15</td>
<td>Closing remarks</td>
</tr>
</tbody>
</table>

MEETING CLOSURE

*pending confirmation*